Literature DB >> 53370

Effect of group-A meningococcal vaccine in army recruits in Finland.

P H Mäkelä, H Käyhty, P Weckström, A Sivonen, O V Renkonen.   

Abstract

During an epidemic caused by group-A, sulphonamide-resistant meningococci in Finland, group-A polysaccharide vaccine was administered in 1974 to 16 458 recruits of the Armed Forces, leaving 20 748 as controls. Specific antibody response was good, and after vaccination only 1% of the men were without anti-meningococcal group-A antibodies. Pharyngeal carriage of the epidemic strain was low, about 1-5%, in the men when entering service. Group-A meningococcal disease occurred during the nine months' mean observation period in 1 of the vaccinated men (an annual incidence of 11 per 100 000) and in 8 of those not vaccinated (71 per 100 000), indicating 89% protective effect of the vaccine. Furthermore, the total number of cases of group-A meningococcal disease was reduced to non-epidemic levels at a time when 36% of the men in service were vaccinated, and has remained low for the next twelve months even though the epidemic in the general population continued.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 53370     DOI: 10.1016/s0140-6736(75)92125-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  31 in total

1.  Determination of meningococcal antibodies by microassay.

Authors:  F Ambrosch; H Stemberger; G Wiedermann; G Stanek; D Jovanovic
Journal:  Bull World Health Organ       Date:  1978       Impact factor: 9.408

2.  Guidelines for controlling meningococcal disease.

Authors: 
Journal:  CMAJ       Date:  1992-03-15       Impact factor: 8.262

3.  Dramatic decline of serogroup C meningococcal disease incidence in Catalonia (Spain) 24 months after a mass vaccination programme of children and young people.

Authors:  L Salleras; A Domínguez; G Prats; I Parron; P Muñoz
Journal:  J Epidemiol Community Health       Date:  2001-04       Impact factor: 3.710

4.  Immunogenicity of meningococcal polysaccharide ACWY vaccine in primary immunized or revaccinated adults.

Authors:  C Ferlito; R Biselli; M S Cattaruzza; R Teloni; S Mariotti; E Tomao; G Salerno; M S Peragallo; P Lulli; S Caporuscio; A Autore; G Bizzarro; V Germano; M I Biondo; A Picchianti Diamanti; S Salemi; R Nisini; R D'Amelio
Journal:  Clin Exp Immunol       Date:  2018-09-20       Impact factor: 4.330

5.  Use of antiserum agar plates for serogrouping of meningococci.

Authors:  A Sivonen; O V Renkonen; J B Robbins
Journal:  J Clin Pathol       Date:  1977-09       Impact factor: 3.411

6.  Prospects for new vaccines.

Authors:  A J Beale
Journal:  Postgrad Med J       Date:  1976-09       Impact factor: 2.401

7.  Editorial: Vaccination against meningitis.

Authors: 
Journal:  Br Med J       Date:  1976-04-17

8.  Safety and immunogenicity of group Y and group W135 meningococcal capsular polysaccharide vaccines in adults.

Authors:  J M Griffiss; B L Brandt; P L Altieri; G B Pier; S L Berman
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

9.  Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults.

Authors:  E L Anderson; T Bowers; C M Mink; D J Kennedy; R B Belshe; H Harakeh; L Pais; P Holder; G M Carlone
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

Review 10.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.